Copyright
©The Author(s) 2020.
World J Virol. Dec 15, 2020; 9(5): 67-78
Published online Dec 15, 2020. doi: 10.5501/wjv.v9.i5.67
Published online Dec 15, 2020. doi: 10.5501/wjv.v9.i5.67
Clinical trial number | Location | Status | Condition | Intervention | Results |
NCT04428008 | United States | Not yet recruiting | COVID-19 | Drug: Thymalfasin | Not yet available |
NCT04487444 | United States | Recruiting | COVID-19 | Drug: Thymalfasin | Not yet available |
NCT04268537 | China | Not yet recruiting | COVID-19 | Drug: PD-1 blocking antibody + standard treatment; Drug: Thymosin + Standard treatment; Other: Standard treatment | Not yet available |
NCT04320238 | China | Recruiting | COVID-19 | Drug: Recombinant human interferon Alpha-1b; Drug: Thymosin alpha 1 | Not yet available |
- Citation: Dominari A, Hathaway III D, Pandav K, Matos W, Biswas S, Reddy G, Thevuthasan S, Khan MA, Mathew A, Makkar SS, Zaidi M, Maher M, Beas R, Castaneda V, Paul T, Halpern J, Baralt D. Thymosin alpha 1: A comprehensive review of the literature. World J Virol 2020; 9(5): 67-78
- URL: https://www.wjgnet.com/2220-3249/full/v9/i5/67.htm
- DOI: https://dx.doi.org/10.5501/wjv.v9.i5.67